Vaxxinity, Inc. announced a collaboration with the University of Central Florida (UCF) to advance space medicine research. The research, funded by a grant from the State of Florida, aims to further the development of Vaxxinity’s active immunotherapies to prevent and mitigate muscle and bone wasting, which are well known health challenges related to long-term spaceflight, and which share biological mechanisms implicated in highly prevalent age-related diseases.
Research will include studies to assess the effects of Vaxxinity’s active immunotherapies on undisclosed proteins implicated with bone and muscle growth through in vitro and in vivo experiments, and animal models established by UCF.
Vaxxinity’s platform is designed to harness and selectively activate the immune system by overcoming immune tolerance, stimulating the production of antibodies against endogenous targets. The company will provide materials including candidates derived from its platform to support the collaborative research at UCF.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!